Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.78 |
| ▸ | PI4KA | P42356 | 1/20 | 0.62 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.62 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.62 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.62 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.59 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.59 |
| ▸ | AMD1 | P17707 | 2/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13662861 | 1.00 | RXFP1 (0.78) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL11759931 | 0.91 | RXFP1 (0.63) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL13926698 | 0.89 | RXFP1 (0.61) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| Water SCHEMBL9941081 | 0.89 | RXFP1 (0.61) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL15390016 | 0.88 | RXFP1 (0.61) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4160501 | 0.88 | RXFP1 (0.62) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4152356 | 0.88 | RXFP1 (0.60) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL2292456 | 0.88 | RXFP1 (0.86) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL12379249 | 0.88 | RXFP1 (0.86) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL16351391 | 0.86 | RXFP1 (0.58) | RXFP1P2RX3P2RX4ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. | 2016-03-10 | — | — | US | disclosed |
| US-9029343-B2 | Modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20070280946-A1 | Antibody to 5' -Deoxy-5' - Methylthioadenosine And Uses Thereof | QUARK PHARMACUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070280946-A1 | Antibody to 5' -Deoxy-5' - Methylthioadenosine And Uses Thereof | QUARK PHARMACUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| EP-1844062-A2 | INHIBITORS OF DNA METHYLTRANSFERASE | Methylgene, Inc. (CA) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006078752-A2 | INHIBITORS OF DNA METHYLTRANSFERASE | METHYLGENE, INC. (CA) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070280946-A1 | Antibody to 5' -Deoxy-5' - Methylthioadenosine And Uses Thereof | MTAP, SRM, NT5C2 | RXFP1 4751/4885PI4KA 4069/4885PI4K2B 4029/4885 |
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | EHMT1, EHMT2, HNMT | RXFP1 4531/4885PI4KA 1844/4885PI4K2B 1901/4885 |
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | EHMT1, EHMT2, HNMT | RXFP1 4531/4885PI4KA 1844/4885PI4K2B 1901/4885 |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | DNMT3B, DNMT1, DNMT3L | RXFP1 4723/4885PI4KA 2879/4885PI4K2B 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.